NO940436L - Forlenget avgivelse av peptider - Google Patents

Forlenget avgivelse av peptider

Info

Publication number
NO940436L
NO940436L NO940436A NO940436A NO940436L NO 940436 L NO940436 L NO 940436L NO 940436 A NO940436 A NO 940436A NO 940436 A NO940436 A NO 940436A NO 940436 L NO940436 L NO 940436L
Authority
NO
Norway
Prior art keywords
peptides
prolonged delivery
administration
prolonged
disclosed
Prior art date
Application number
NO940436A
Other languages
English (en)
Other versions
NO940436D0 (no
NO318804B1 (no
Inventor
Dennis Edward Danley
Robert Alan Gelfand
Kieran Francis Geoghegan
Yesook Kim
William Joseph Lambert
Hong Qi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO940436D0 publication Critical patent/NO940436D0/no
Publication of NO940436L publication Critical patent/NO940436L/no
Publication of NO318804B1 publication Critical patent/NO318804B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Optical Communication System (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19940436A 1993-04-07 1994-02-09 Stoffsammensetninger og anvendelse derav. NO318804B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4413393A 1993-04-07 1993-04-07

Publications (3)

Publication Number Publication Date
NO940436D0 NO940436D0 (no) 1994-02-09
NO940436L true NO940436L (no) 1994-10-10
NO318804B1 NO318804B1 (no) 2005-05-09

Family

ID=21930680

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19940436A NO318804B1 (no) 1993-04-07 1994-02-09 Stoffsammensetninger og anvendelse derav.

Country Status (19)

Country Link
EP (1) EP0619322B1 (no)
JP (5) JPH072695A (no)
KR (1) KR100186885B1 (no)
CN (2) CN1311865C (no)
AT (1) ATE314393T1 (no)
AU (1) AU682328B2 (no)
BR (1) BR9401185A (no)
CA (1) CA2116478C (no)
CZ (1) CZ296341B6 (no)
DE (1) DE69434588T2 (no)
ES (1) ES2255051T3 (no)
HK (1) HK1070589A1 (no)
HU (1) HU225496B1 (no)
IL (1) IL108611A (no)
NO (1) NO318804B1 (no)
NZ (1) NZ250844A (no)
PL (1) PL180697B1 (no)
RU (1) RU2126264C1 (no)
ZA (1) ZA94878B (no)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
JPH0682743A (ja) * 1992-09-04 1994-03-25 Sony Corp 強誘電性液晶組成物
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
EP0658568A1 (en) * 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
EP0796106B1 (en) * 1994-12-23 2003-03-19 Novo Nordisk A/S Protracted glp-1 compositions
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DE19530865A1 (de) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
CA2243718A1 (en) * 1996-02-06 1997-08-14 Eli Lilly And Company Diabetes therapy
JPH10513202A (ja) * 1996-06-11 1998-12-15 ゾナジェン，インコーポレイテッド キトサン薬物送達システム
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2002510193A (ja) * 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
AU751182B2 (en) * 1997-12-02 2002-08-08 Archimedes Development Limited Compositions for nasal administration
AU1617399A (en) * 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
EP2028269B1 (en) 1998-08-10 2015-10-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4 and uses thereof
EP1666054A1 (en) * 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
JP2002523466A (ja) * 1998-08-28 2002-07-30 イーライ・リリー・アンド・カンパニー インスリン向性ペプチドの投与方法
BR0010705A (pt) 1999-04-30 2002-02-05 Amylin Pharmaceuticals Inc Exendinas modificadas e agonistas da exendina
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
IL149355A0 (en) * 1999-10-28 2002-11-10 Inst Neftechimicheskogo Sintez Polypeptide corporation
ES2218381T3 (es) 2000-01-27 2004-11-16 Eli Lilly And Company Procedimiento para solubilizar compuestos del peptido 1 de tipo glucagon.
EP1396499A3 (en) * 2000-01-27 2004-12-29 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
WO2001057084A1 (en) * 2000-01-31 2001-08-09 Novo Nordisk A/S Crystallisation of a glp-1 analogue
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
WO2002043709A1 (fr) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
EP1351984A2 (en) 2000-12-13 2003-10-15 Eli Lilly And Company Amidated glucagon-like peptide-1
JP2005506956A (ja) 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
CA2458371A1 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
US20050148497A1 (en) 2002-02-20 2005-07-07 Khan Mohammed A. Method for administering glp-1 molecules
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
NZ554885A (en) * 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
JP4548335B2 (ja) * 2003-03-07 2010-09-22 味の素株式会社 腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
SI1605897T1 (sl) * 2003-03-19 2012-11-30 Lilly Co Eli Polietilen glikol povezane GLP spojine
ES2393292T3 (es) 2003-06-03 2012-12-20 Rib-X Pharmaceuticals, Inc. Compuestos heterocíclicos de biarilo y métodos de obtención y uso de los mismos
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
TWI353250B (en) 2003-12-16 2011-12-01 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
KR20070094909A (ko) * 2004-12-02 2007-09-27 도만티스 리미티드 혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
KR20080028981A (ko) 2005-06-30 2008-04-02 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Ｇｌｐ-1 약학 조성물
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
EP2015769A4 (en) * 2006-04-13 2013-12-25 Ipsen Pharma PHARMACEUTICAL COMPOSITIONS OF HGLP-1, EXENDINE 4 AND THEIR ANALOGUES
JP2009534423A (ja) 2006-04-20 2009-09-24 アムジェン インコーポレイテッド Ｇｌｐ−１化合物
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EA020019B1 (ru) * 2008-08-07 2014-08-29 Ипсен Фарма С.А.С. Аналоги глюкозозависимого инсулинотропного полипептида
WO2010016935A2 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
US9072703B2 (en) * 2008-08-07 2015-07-07 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
CN106880596A (zh) * 2008-10-15 2017-06-23 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
KR102148624B1 (ko) 2009-09-28 2020-08-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
US20120157382A1 (en) 2010-12-21 2012-06-21 Siegfried Krimmer Pharmaceutical glp-1 compositions having an improved release profile
US20140045754A1 (en) * 2011-01-19 2014-02-13 Joern Drustrup Glp-1 compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102643339B (zh) * 2011-02-21 2014-04-09 天津药物研究院 一种glp-1类似物、制备方法及其应用
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
RU2652783C2 (ru) 2012-12-21 2018-05-03 Санофи Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона
US9528648B2 (en) 2013-03-15 2016-12-27 Opw Fueling Components Inc. Breakaway assembly with relief valve
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
CN113912673B (zh) * 2021-11-09 2024-02-09 河南省农业科学院 一种芝麻来源的低苦味ace抑制肽及其制备方法和应用
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
WO1989003671A1 (en) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Sustained-release preparation
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
ATE193541T1 (de) * 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
CA2073856C (en) * 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5069223A (en) * 1990-02-14 1991-12-03 Georgetown University Method of evaluating tissue changes resulting from therapeutic hyperthermia
PL166951B1 (pl) * 1990-06-15 1995-07-31 Schering Corp Sposób wytwarzania tetragonalnych krysztalów ludzkiej interleukiny-4 PL PL PL PL
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat

Also Published As

Publication number Publication date
JP2004099621A (ja) 2004-04-02
BR9401185A (pt) 1994-10-18
DE69434588D1 (de) 2006-02-02
AU682328B2 (en) 1997-10-02
JPH072695A (ja) 1995-01-06
CN1311865C (zh) 2007-04-25
CZ27594A3 (en) 1995-05-17
EP0619322A2 (en) 1994-10-12
KR100186885B1 (ko) 1999-05-01
HUT68525A (en) 1995-06-28
CN1544084A (zh) 2004-11-10
EP0619322A3 (en) 1996-03-13
ZA94878B (en) 1995-08-10
HK1070589A1 (en) 2005-06-24
NO940436D0 (no) 1994-02-09
CN1080123C (zh) 2002-03-06
ES2255051T3 (es) 2006-06-16
PL180697B1 (pl) 2001-03-30
CN1106698A (zh) 1995-08-16
IL108611A0 (en) 1994-05-30
RU2126264C1 (ru) 1999-02-20
IL108611A (en) 2004-06-20
JP2006213727A (ja) 2006-08-17
HU9400350D0 (en) 1994-05-30
JP5081213B2 (ja) 2012-11-28
EP0619322B1 (en) 2005-12-28
AU5501694A (en) 1994-10-13
DE69434588T2 (de) 2006-09-07
NO318804B1 (no) 2005-05-09
JP2010006841A (ja) 2010-01-14
CA2116478A1 (en) 1994-10-08
CZ296341B6 (cs) 2006-02-15
JP2001158749A (ja) 2001-06-12
NZ250844A (en) 1996-03-26
JP4610503B2 (ja) 2011-01-12
ATE314393T1 (de) 2006-01-15
CA2116478C (en) 2002-12-03
HU225496B1 (en) 2007-01-29

Similar Documents

Publication Publication Date Title
NO940436D0 (no) Forlenget avgivelse av peptider
AU3888893A (en) Use of a peptide
DE68929217D1 (en) Insulinotropes hormon
AU3372595A (en) Biologically active fragments of glucagon-like insulinotropic peptide
PL319608A1 (en) Compositions for treating irds and ards, containing at least one glucocorticosteroid in a mixture with a pulmonic surfactant
AU564648B2 (en) Insulin agent
EP0728477A3 (no)
AU2373400A (en) Shelf-stable formulation of glucagon-like peptide-1
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
EP2022505A3 (en) GLP-1, exendin-4, peptide analogs and uses thereof
CA2138161A1 (en) Glucagon-like peptide and insulinotropin derivatives
DK2016950T3 (da) Farmaceutisk sammensætning omfattende et exendin-4-peptid
DE60124710D1 (de) Analoge des glucagon ähnlichen peptid-1
ZA896149B (en) Pharmaceutical formulation for the treatment of diabetes mellitus
AU5446590A (en) Drugs (calcitonin gene-related peptides) for treating erectile dysfunctions
MX9201110A (es) Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados.
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
EP0672060A4 (en) ANTIGEN ASSOCIATED WITH TYPE I SUGAR DIABETES
CA2120626A1 (en) Method for enhancing gut absorption
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
UY25103A1 (es) Composición para el tratamiento de diabetes mellitus
BG104058A (en) Diabetes treatment with thiazolydindion and sulphonylurea
SE8204871D0 (sv) Farmaceutiska preparat, innefattande humant proinsulin
SE8204872D0 (sv) Farmaceutiska preparat, innefattande humant insulin, human c-peptid och humant proinsulin

Legal Events

Date Code Title Description
MK1K Patent expired